Pediatric Mycoplasma Pneumonia Patient Data with Biomarkers from Shanghai, 2023-2024

147 pediatric patient records from a Shanghai hospital study the association of soluble ST2 (sST2) with severe adverse events in Mycoplasma pneumoniae pneumonia. The dataset includes demographic, clinical, and laboratory data such as inflammatory markers and blood cell counts. Author Fangying Cheng published the data under a CC-BY-4.0 license in 2026.

Use Cases

• Predicting severe in-hospital adverse events based on sST2 biomarker levels.
• Analyzing correlations between sST2 and other inflammatory markers like CRP, PCT, and IL-6.
• Investigating associations between biomarker levels and clinical outcomes like ICU admission or sepsis.
• Modeling the relationship between sST2 levels and patient factors such as hospital length of stay or fever duration.

Strengths

• Dataset is focused on a specific clinical question with a defined cohort of 147 pediatric patients.
• Includes a key biomarker (sST2) with a statistically significant predictive performance (AUC=0.944) for severe events.
• Data collection covers multiple clinical and laboratory variables, as mentioned in the study description.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect geographic and temporal bias inherent to a single hospital study in Shanghai over 14 months.

Provenance

Source

Fangying Cheng, likely affiliated with the Children’s Hospital of Fudan University.

Collection Method

Retrospective analysis of hospital admissions.

Time Range

01/04/2023 to 31/05/2024

Freshness

Last updated 2026-04-17 17:43:44; freshness should be verified.

Geography

Shanghai, China